BMS的Opdivo/Yervoy组合治疗肝细胞癌,获得FDA的优先审查

2019-11-17 不详 MedSci原创

百时美施贵宝公司宣布其Opdivo/Yervoy组合用于先前接受过治疗的肝细胞癌患者,喜获美国食品药品监督管理局(FDA)的优先审核。

百时美施贵宝公司宣布其Opdivo/Yervoy组合用于先前接受过治疗的肝细胞癌患者,喜获美国食品药品监督管理局(FDA)的优先审核。

肝细胞癌(HCC)是最常见的原发性肝癌,通常诊断为晚期,预后较差。肝癌患者的治疗选择有限,近年来只有少数新药被批准用于二线治疗。

BMS的1/2 CheckMate-040研究获得了FDA的优先评估,以评估Opdivo(nivolumab)和Yervoy(ipilimumab)用于先前用拜耳的Nexavar(sorafenib)治疗过的HCC患者。

BMS胃肠道癌症研究负责人Ian Waxman说:"对于美国的肝癌患者来说,FDA接受我们Opdivo/ Yervoy的优先审核申请代表了重要的进展。肝细胞癌仍然是一种难以治疗的癌症,患者需要更多有效的治疗选择。我们期待与FDA合作,将该双重肿瘤免疫疗法带给患者。"

BMS先前已将Opdivo评估为一线肺癌的单药治疗方法,尽管该领域的努力没有成果。Opdivo在HCC的一线治疗中未显示出疗效,因为与CheckMate-459研究中的Nexavar相比, OS改善的趋势并没有达到统计学上的显着性。

Opdivo已被批准用作HCC的单药治疗二线治疗药物,但如果获得批准,该组合药有望获得其更多的市场份额。

BMS还希望将该组合用于肺癌的治疗,最近的一项 3期试验证明Opdivo / Yervoy在一线晚期非小细胞肺癌NSCLC)中取得了积极成果。但是,该市场以默克公司的Keytruda(派姆单抗)为主导,该方案已被广泛用于新诊断的NSCLC患者。

Opdivo / Yervoy组合的希望是为BMS的明星PD-1检查点抑制剂带来显着增长,在其第三季度业绩中,该公司透露 Opdivo仅增长1%至18.2亿美元,销售额下滑5%。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1863461, encodeId=07731863461f5, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jul 30 04:45:00 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978909, encodeId=d84b19e8909a4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Nov 24 14:45:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303084, encodeId=c73c13030845c, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365811, encodeId=9fbf1365811ef, content=<a href='/topic/show?id=5b751895214' target=_blank style='color:#2F92EE;'>#Yervoy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18952, encryptionId=5b751895214, topicName=Yervoy)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378674, encodeId=3fa313e867445, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400142, encodeId=bf3b140014286, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25729, encryptionId=0b0e25e2913, topicName=优先审查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80942248041, createdName=yxch37, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2020-07-30 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=1863461, encodeId=07731863461f5, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jul 30 04:45:00 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978909, encodeId=d84b19e8909a4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Nov 24 14:45:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303084, encodeId=c73c13030845c, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365811, encodeId=9fbf1365811ef, content=<a href='/topic/show?id=5b751895214' target=_blank style='color:#2F92EE;'>#Yervoy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18952, encryptionId=5b751895214, topicName=Yervoy)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378674, encodeId=3fa313e867445, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400142, encodeId=bf3b140014286, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25729, encryptionId=0b0e25e2913, topicName=优先审查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80942248041, createdName=yxch37, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1863461, encodeId=07731863461f5, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jul 30 04:45:00 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978909, encodeId=d84b19e8909a4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Nov 24 14:45:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303084, encodeId=c73c13030845c, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365811, encodeId=9fbf1365811ef, content=<a href='/topic/show?id=5b751895214' target=_blank style='color:#2F92EE;'>#Yervoy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18952, encryptionId=5b751895214, topicName=Yervoy)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378674, encodeId=3fa313e867445, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400142, encodeId=bf3b140014286, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25729, encryptionId=0b0e25e2913, topicName=优先审查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80942248041, createdName=yxch37, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-11-19 119337457
  4. [GetPortalCommentsPageByObjectIdResponse(id=1863461, encodeId=07731863461f5, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jul 30 04:45:00 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978909, encodeId=d84b19e8909a4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Nov 24 14:45:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303084, encodeId=c73c13030845c, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365811, encodeId=9fbf1365811ef, content=<a href='/topic/show?id=5b751895214' target=_blank style='color:#2F92EE;'>#Yervoy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18952, encryptionId=5b751895214, topicName=Yervoy)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378674, encodeId=3fa313e867445, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400142, encodeId=bf3b140014286, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25729, encryptionId=0b0e25e2913, topicName=优先审查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80942248041, createdName=yxch37, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-11-19 gostraight
  5. [GetPortalCommentsPageByObjectIdResponse(id=1863461, encodeId=07731863461f5, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jul 30 04:45:00 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978909, encodeId=d84b19e8909a4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Nov 24 14:45:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303084, encodeId=c73c13030845c, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365811, encodeId=9fbf1365811ef, content=<a href='/topic/show?id=5b751895214' target=_blank style='color:#2F92EE;'>#Yervoy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18952, encryptionId=5b751895214, topicName=Yervoy)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378674, encodeId=3fa313e867445, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400142, encodeId=bf3b140014286, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25729, encryptionId=0b0e25e2913, topicName=优先审查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80942248041, createdName=yxch37, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]
    2019-11-19 canlab
  6. [GetPortalCommentsPageByObjectIdResponse(id=1863461, encodeId=07731863461f5, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jul 30 04:45:00 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978909, encodeId=d84b19e8909a4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Nov 24 14:45:00 CST 2019, time=2019-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303084, encodeId=c73c13030845c, content=<a href='/topic/show?id=4264134043c' target=_blank style='color:#2F92EE;'>#Opdivo#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13404, encryptionId=4264134043c, topicName=Opdivo)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365811, encodeId=9fbf1365811ef, content=<a href='/topic/show?id=5b751895214' target=_blank style='color:#2F92EE;'>#Yervoy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18952, encryptionId=5b751895214, topicName=Yervoy)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378674, encodeId=3fa313e867445, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400142, encodeId=bf3b140014286, content=<a href='/topic/show?id=0b0e25e2913' target=_blank style='color:#2F92EE;'>#优先审查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25729, encryptionId=0b0e25e2913, topicName=优先审查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80942248041, createdName=yxch37, createdTime=Tue Nov 19 10:45:00 CST 2019, time=2019-11-19, status=1, ipAttribution=)]

相关资讯

同单纯置入BMS相比DEB预扩后置入BMS无临床效果优势(DEB-AMI研究)

    来自荷兰和意大利的DEB-AMI试验6个月随访发现,药物洗脱球囊预扩后置入裸金属支架(DEB加BMS)后造影结果并不优于单纯置入裸金属支架(BMS);药物洗脱支架(DES)造影结果比BMS或DEB加BMS更好。此外,和BMS相比,支架置入前以DEB预扩会导致更多的支架贴壁不良和覆盖不良,不过,该两种情况发生仍少于置入DES的患者。研究4月11日在线发表于《美国心脏病学会杂志》(

市值935亿美元的BMS要卖?辉瑞罗氏诺华吉列德钱多到烧手……

据FiercePharma消息,进入2017年之后,BMS被多名分析师列入潜在并购标的推荐之中。他们为何会向药企客户提出可以考虑收购几乎在免疫肿瘤领域“称王称霸”的BMS?这是怎么回事?潜在买家中,辉瑞再次出现。结合之前收购阿斯利康出价1170亿美元,如果这次辉瑞真的出手,又会是个什么价格?可以比较的是,BMS市值比阿斯利康高出了整整300多亿美元,而且这家公司的核心产品可都是全球最热的免疫肿瘤类

历史性一刻,BMS单抗Opdivo强势来袭,中国**款提交上市申请的PD-1/PD-L1类药物

11月2日,百时美施贵宝提交了Opdivo的上市申请(JXSS1700015)得到了CDE受理。而Opdivo也将历史性的成为中国第一款提交上市申请的PD-1/PD-L1类药物!

Oncotarget:PD-1 / PD-L1免疫检查点的小分子抑制剂能够减轻PD-L1诱导的T细胞耗竭

尽管针对PD-1 / PD-L1免疫检查点的抗体近年来在抗癌治疗方面取得了令人瞩目的成就。 相比之下,目前仍没有针对PD-1 / PD-L1免疫检查点的小分子化合物的报道,相比于经静脉注射给药或皮下注射给药方式,小分子独有的口服给药方式会极大提高患者的依从性。近日波兰学者在Oncotarget杂志中报道了几种小分子能够减轻PD-1 / PD-L1免疫检查点介导的Jurkat T淋巴细胞衰竭,这两种

BMS拟将其糖尿病药物股份以30亿美元出让AZ

12月18日,《华尔街日报》报道说,百时美施贵宝(BMS)在一项交易中打算将其与阿斯利康(AZ)合伙经营的糖尿病药物股份以30多亿美元的价值出让给该英国制药商。百时美施贵宝上个月已宣布将不再进行糖尿病、丙型肝炎及神经系统疾病新药的研究与开发,但对通过利用自身免疫系统来抗击癌症的药物将增加研发投入。那次重新调整使人们推测百时美施贵宝将寻求出让其与阿斯利康合资经营的糖尿病药物的非美国股份。百时美施贵宝

BMS和辉瑞宣布与Fitbit合作推动房颤可穿戴设备的及时诊断

百时美施贵宝(Bristol-Myers Squibb)和辉瑞(Pfizer)两家药业巨头宣布,他们正在与Fitbit结盟,以帮助推动及时诊断房颤(AFib)。